[go: up one dir, main page]

MX354743B - Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi). - Google Patents

Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).

Info

Publication number
MX354743B
MX354743B MX2014010845A MX2014010845A MX354743B MX 354743 B MX354743 B MX 354743B MX 2014010845 A MX2014010845 A MX 2014010845A MX 2014010845 A MX2014010845 A MX 2014010845A MX 354743 B MX354743 B MX 354743B
Authority
MX
Mexico
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
MX2014010845A
Other languages
English (en)
Inventor
Junliang Pan
Zhuozhi Wang
Jan Tebbe
Joanna Grudzinska
Christian Votsmeier
Joerg Birkenfeld
Nina Wobst
Peter Scholz
Simone Brueckner
Susanne Steinig
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44542552&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354743(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX354743B publication Critical patent/MX354743B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Filtering Materials (AREA)

Abstract

La presente invención se refiere a anticuerpos monoclonales aislados que se unen al inhibidor de la vía del factor tisular (TFPI) humano. También se contemplan las moléculas de ácido nucleico aisladas que codifican anticuerpos monoclonales que se unen al TFPI. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos monoclonales anti-TFPI y procedimientos de tratamiento de deficiencias o defectos en la coagulación mediante administración de los anticuerpos. También se proporcionan procedimientos para producir los anticuerpos.
MX2014010845A 2010-03-01 2012-09-03 Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi). MX354743B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30929010P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
MX354743B true MX354743B (es) 2018-03-16

Family

ID=44542552

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012010198A MX2012010198A (es) 2010-03-01 2011-03-01 Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
MX2014010845A MX354743B (es) 2010-03-01 2012-09-03 Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2012010198A MX2012010198A (es) 2010-03-01 2011-03-01 Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).

Country Status (37)

Country Link
US (3) US9309324B2 (es)
EP (2) EP3345615B1 (es)
JP (4) JP6025570B2 (es)
KR (4) KR101903931B1 (es)
CN (5) CN105001335B (es)
AU (1) AU2011223710B2 (es)
BR (1) BR112012022258A2 (es)
CA (3) CA2976671C (es)
CL (2) CL2012002415A1 (es)
CO (1) CO6620068A2 (es)
CR (1) CR20120453A (es)
CU (1) CU23982B1 (es)
CY (2) CY1119410T1 (es)
DK (2) DK3345615T3 (es)
DO (1) DOP2012000239A (es)
EA (2) EA032189B9 (es)
EC (2) ECSP12012134A (es)
ES (2) ES2642512T3 (es)
GT (1) GT201200252A (es)
HK (2) HK1232232A1 (es)
HR (2) HRP20171472T1 (es)
HU (2) HUE047173T2 (es)
IL (3) IL221551B (es)
LT (2) LT2542257T (es)
ME (2) ME03578B (es)
MX (2) MX2012010198A (es)
MY (1) MY174760A (es)
NZ (2) NZ602115A (es)
PE (1) PE20160538A1 (es)
PH (4) PH12012501742A1 (es)
PL (2) PL2542257T3 (es)
PT (2) PT2542257T (es)
RS (2) RS56409B1 (es)
SG (3) SG10201502587SA (es)
SI (2) SI3345615T1 (es)
SM (1) SMT201700454T1 (es)
WO (1) WO2011109452A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP5714505B2 (ja) 2008-12-22 2015-05-07 ノヴォ ノルディスク アー/エス 組織因子経路阻害因子に対する抗体
PT2542257T (pt) * 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2012001087A1 (en) * 2010-06-30 2012-01-05 Novo Nordisk A/S Antibodies that are capable of specifically binding tissue factor pathway inhibitor
PL2694544T3 (pl) * 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
RU2014143639A (ru) * 2012-03-30 2016-05-27 Байер Хелскеа Ллк Регулируемые протеазой антитела
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AR095502A1 (es) * 2013-03-15 2015-10-21 Bayer Healthcare Llc Anticuerpos profármaco contra el inhibidor de la vía del factor tisular
RS56814B1 (sr) * 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
US10266607B2 (en) * 2015-02-25 2019-04-23 Mogam Institute For Biomedical Research Antibody binding to TFPI and composition comprising the same
CN107922506B (zh) * 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
EP3863664A1 (en) 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists
KR102692277B1 (ko) * 2019-03-11 2024-08-05 현대자동차주식회사 상용 전기차용 모터 마운트
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN117285632A (zh) * 2022-06-17 2023-12-26 安源医药科技(上海)有限公司 针对tfpi的单克隆抗体及其用途

Family Cites Families (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1064396A (en) 1975-02-18 1979-10-16 Myer L. Coval Fractional precipitation of gamma globulin with polyethylene glycol
US4075193A (en) 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
EP0303746B2 (en) 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5217954A (en) 1990-04-04 1993-06-08 Scios Nova Inc. Formulations for stabilizing fibroblast growth factor
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6165467A (en) 1991-07-20 2000-12-26 Yoshihide Hagiwara Stabilized human monoclonal antibody preparation
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
US5849700A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DE4223132A1 (de) 1992-07-14 1994-01-20 Deutsche Aerospace Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
RU2143889C1 (ru) 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE4344824C1 (de) 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
JPH0875736A (ja) 1994-09-06 1996-03-22 Chemo Sero Therapeut Res Inst ヒト組織因子凝固系インヒビターの定量法
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
US6111079A (en) 1995-06-05 2000-08-29 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefore
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US6686191B1 (en) 1995-09-22 2004-02-03 Bayer Healthcare Llc Preparation of virally inactivated intravenously injectable immune serum globulin
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
JP3681206B2 (ja) * 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
WO1997026862A2 (de) 1996-01-25 1997-07-31 Schering Aktiengesellschaft Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US20040052799A1 (en) 1996-11-15 2004-03-18 Astra Aktiebolag Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
CA2285702C (en) 1997-03-26 2016-06-28 Rpms Technology Limited Anticoagulant fusion protein anchored to cell membrane
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6617156B1 (en) 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
EP1005776B1 (de) 1997-08-21 2003-01-08 Siemens Aktiengesellschaft Verfahren zum übertragen von nutzdaten, die unterschiedlichen anwendungen zuordenbar sind
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
AU3006799A (en) 1998-03-12 1999-09-27 Human Genome Sciences, Inc. 31 human secreted proteins
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
IL149008A0 (en) 1999-10-04 2002-11-10 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
JP4623825B2 (ja) 1999-12-16 2011-02-02 協和発酵バイオ株式会社 新規ポリヌクレオチド
US20020160934A1 (en) 2000-01-14 2002-10-31 Julie Broadus Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
JP4683810B2 (ja) 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤
ATE363915T1 (de) 2000-04-07 2007-06-15 Signal Coordinating Therapy In Methoden und zusammensetzungen zur behandlung von neoplasmen
US20110131679A2 (en) 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
US20040181830A1 (en) 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US20020082206A1 (en) 2000-05-30 2002-06-27 Leach Martin D. Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
EP1336410A4 (en) 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
WO2002013860A1 (fr) 2000-08-11 2002-02-21 Chugai Seiyaku Kabushiki Kaisha Preparations stabilisees contenant un anticorps
KR20030027077A (ko) 2000-09-01 2003-04-03 쥬가이 세이야쿠 가부시키가이샤 장기 안정화 용액 제제
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
GB0101879D0 (en) 2001-01-24 2001-03-07 Enzyme Res Lab Ltd Anticoagulants and their uses
AU2002339119A1 (en) 2001-02-07 2002-12-03 Centre National De La Recherche Scientifique (Cnrs) Sequence of the photorhabdus luminescens strain tt01 genome and uses
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US6891085B2 (en) 2001-04-20 2005-05-10 Pioneer Hi-Bred International, Inc. Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
AU2002302247A1 (en) 2001-05-21 2002-12-03 Ecopia Biosciences Inc. Genes and proteins involved in the biosynthesis of enediyne ring structures
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CN1571797A (zh) 2001-10-15 2005-01-26 麒麟麦酒株式会社 抗hla-dr抗体
BR0213298A (pt) 2001-10-16 2006-11-07 Rxkinetix Inc formulações com alta concentração de proteìna e processo de fabricação
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003037172A2 (en) 2001-11-01 2003-05-08 Gpc Biotech Inc. Endothelial-cell binding peptides for diagnosis and therapy
NZ532896A (en) 2001-11-08 2007-08-31 Pdl Biopharma Inc Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
AU2002363925A1 (en) 2001-11-29 2003-06-17 Wyeth Holdings Corporation ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF
US20030138416A1 (en) 2001-12-03 2003-07-24 Jesper Lau Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
JP2005522999A (ja) 2002-01-31 2005-08-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 癌を処置するための方法および組成物
CN101721362B (zh) 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
WO2003076575A2 (en) 2002-03-04 2003-09-18 Fidelity Systems, Inc., Et Al. The complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
US7074559B2 (en) 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
CA2492143A1 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
DE10239073A1 (de) 2002-08-26 2004-03-11 Basf Ag Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
BR0315164A (pt) 2002-10-08 2005-08-23 Rinat Neuroscience Corp Métodos para tratar dor pós-cirúrgica administrando um antagonista de fator de crescimento nervoso e composições contendo o mesmo
KR100542401B1 (ko) 2002-10-23 2006-01-11 한국전자통신연구원 인터넷 차별 서비스 망에서의 연결 수락 제어방법
EP1578947A4 (en) 2002-12-02 2006-12-06 Abgenix Inc ANTIBODIES TAKEN AGAINST PHOSPHOLIPASE A2 AND USES THEREOF
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2003299898B2 (en) 2002-12-24 2010-12-16 Rinat Neuroscience Corp. Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP2853593B1 (en) 2003-03-07 2017-10-04 DSM IP Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CN1930187B (zh) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ES2523837T3 (es) 2003-07-18 2014-12-01 Amgen Inc. Agentes de unión específica al factor de crecimiento de hepatocitos
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US20060107345A1 (en) 2003-09-30 2006-05-18 Nickolai Alexandrov Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
CA2445743A1 (en) 2003-10-08 2005-04-08 The University Of British Columbia Methods for modulating neuronal responses
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
CA2547569C (en) 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
US20070184050A1 (en) 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
WO2005069762A2 (en) 2004-01-09 2005-08-04 Novozymes Inc. Bacillus licheniformis chromosome
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
PL2314621T3 (pl) 2004-05-27 2014-08-29 Crucell Holland Bv Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania
CA2564791A1 (en) 2004-06-14 2005-12-29 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
RU2394839C2 (ru) 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
US7566772B2 (en) 2005-01-26 2009-07-28 Amgen Fremont Inc. Antibodies against interleukin-1β
AU2006233353B2 (en) 2005-01-27 2011-12-15 Swedish Orphan Biovitrum Ag Human anti-interferon gamma antibodies and methods of use thereof
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP1841456A2 (en) 2005-01-28 2007-10-10 Wyeth Stabilized liquid polypeptide formulations
BRPI0607639B1 (pt) 2005-02-08 2022-04-05 Genzyme Corporation Moléculas de anticorpo humano ou fragmento de ligação a antígeno das mesmas que se ligam e neutralizam tgf-beta1, 2 e 3, uso das mesmas e composição farmacêutica
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
CA2600907C (en) 2005-03-04 2016-06-28 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
WO2006096489A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2006112838A1 (en) 2005-04-18 2006-10-26 Xtl Biopharmaceuticals Ltd. Stabilized anti-hepatitis b (hbv) antibody formulations
US7889636B2 (en) 2005-05-24 2011-02-15 Cisco Technology, Inc. System and method for implementing a mid-call policy in a RSVP environment
GB2426887B (en) 2005-06-04 2009-01-07 Ibm Client responsibilities in messaging systems
JP5033798B2 (ja) 2005-07-02 2012-09-26 アレコー・リミテッド タンパク質を含む安定水系
AU2006278573A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070086433A1 (en) 2005-10-19 2007-04-19 Cunetto Philip C Methods and apparatus for allocating shared communication resources to outdial communication services
CA2630349A1 (en) 2005-11-21 2007-05-24 Sanofi Pasteur Limited Stabilizing formulations for recombinant viruses
AU2006338198B2 (en) 2005-12-02 2012-04-26 Genentech, Inc. Binding polypeptides and uses thereof
US7669228B2 (en) 2005-12-27 2010-02-23 Cisco Technology, Inc. System and method for changing network behavior based on presence information
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
DE102006005094A1 (de) 2006-02-04 2007-08-09 Degussa Gmbh Titandioxid und Polycarboxylatether enthaltende Dispersion
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US20070224627A1 (en) 2006-03-23 2007-09-27 Lawrence Horowitz Facilitation of translocation of molecules through the gastrointestinal tract
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-egfr 항체의 동결건조 제제
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
US8355333B2 (en) 2006-08-31 2013-01-15 Ciena Corporation Methods and systems for session initiation protocol control of network equipment
US7744890B2 (en) 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
MX2009006199A (es) 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
AR067011A1 (es) 2007-06-14 2009-09-30 Biogen Idec Inc Formulaciones de anticuerpos
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
EP2222707B1 (en) * 2007-11-21 2016-01-06 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
CA2708854C (en) 2007-12-14 2017-11-28 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
UA100255C2 (uk) 2007-12-28 2012-12-10 Біоінвент Інтернешенл Аб Фармацевтична композиція
BRPI0907532A2 (pt) 2008-02-20 2015-07-28 G2 Inflammation Pty Ltd Anticorpos anti-c5ar humanizados
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
EP2297203A1 (en) 2008-06-30 2011-03-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
JP5642683B2 (ja) 2008-09-19 2014-12-17 ファイザー・インク 安定な液体抗体配合物
RU2011126338A (ru) 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102348462B (zh) 2008-12-19 2015-06-17 巴克斯特国际公司 Tfpi抑制剂和使用方法
JP5714505B2 (ja) 2008-12-22 2015-05-07 ノヴォ ノルディスク アー/エス 組織因子経路阻害因子に対する抗体
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
TW201039854A (en) 2009-03-06 2010-11-16 Genentech Inc Antibody formulation
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
ES2531083T3 (es) 2009-09-03 2015-03-10 Ablynx Nv Formulaciones estables de polipéptidos y usos de las mismas
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー/エス 安定な抗体含有組成物
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
EP3146977B1 (en) 2010-03-19 2024-05-08 Takeda Pharmaceutical Company Limited Tfpi inhibitors and methods of use
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
JP6002691B2 (ja) 2011-02-11 2016-10-05 バクスアルタ ゲーエムベーハー 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
PL2694544T3 (pl) 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
US20130267584A1 (en) 2012-03-22 2013-10-10 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RS56814B1 (sr) 2013-03-15 2018-04-30 Bayer Healthcare Llc Varijante anti-tfpi antitela sa diferencijalnim vezivanjem duž ph opsega zarad poboljšanja farmakokinetike
US10266607B2 (en) 2015-02-25 2019-04-23 Mogam Institute For Biomedical Research Antibody binding to TFPI and composition comprising the same
CN107922506B (zh) 2015-08-19 2021-11-09 辉瑞公司 组织因子途径抑制剂抗体及其用途

Also Published As

Publication number Publication date
EP3345615B1 (en) 2019-10-16
PH12012501742A1 (en) 2022-03-21
CA2976671A1 (en) 2011-09-09
KR101974980B1 (ko) 2019-05-07
RS59830B1 (sr) 2020-02-28
CY1122476T1 (el) 2021-01-27
ME03578B (me) 2020-07-20
SG10201903166PA (en) 2019-05-30
MX2012010198A (es) 2012-10-03
IL262444B (en) 2021-01-31
PT3345615T (pt) 2020-01-17
ECSP12012134A (es) 2012-09-28
JP2020115868A (ja) 2020-08-06
EA032189B9 (ru) 2019-09-30
DK2542257T3 (en) 2017-10-16
JP6684369B2 (ja) 2020-04-22
DOP2012000239A (es) 2013-08-15
SG183443A1 (en) 2012-09-27
EA201892184A1 (ru) 2019-03-29
JP2017035100A (ja) 2017-02-16
HUE047173T2 (hu) 2020-04-28
CY1119410T1 (el) 2018-03-07
CN105001335B (zh) 2019-10-25
KR101903931B1 (ko) 2018-10-02
IL221551B (en) 2019-08-29
HK1254947A1 (zh) 2019-08-02
GT201200252A (es) 2014-04-03
DK3345615T3 (da) 2020-01-20
BR112012022258A2 (pt) 2016-10-25
CN107987166A (zh) 2018-05-04
EP3345615A1 (en) 2018-07-11
PH12018500640A1 (en) 2019-07-29
CL2012002415A1 (es) 2013-08-23
PE20160538A1 (es) 2016-05-19
CA2791685A1 (en) 2011-09-09
KR20180091116A (ko) 2018-08-14
CR20120453A (es) 2013-02-27
US9309324B2 (en) 2016-04-12
SMT201700454T1 (it) 2018-01-11
LT2542257T (lt) 2017-11-27
USRE47150E1 (en) 2018-12-04
IL277391A (en) 2020-11-30
RS56409B1 (sr) 2018-01-31
WO2011109452A1 (en) 2011-09-09
HUE036655T2 (hu) 2018-07-30
US20120329996A1 (en) 2012-12-27
KR20170137218A (ko) 2017-12-12
JP6475679B2 (ja) 2019-02-27
CN102939098A (zh) 2013-02-20
MY174760A (en) 2020-05-13
LT3345615T (lt) 2020-02-10
CL2017003218A1 (es) 2018-06-08
ME02894B (me) 2018-04-20
AU2011223710B2 (en) 2016-04-14
PT2542257T (pt) 2017-10-09
JP2019089807A (ja) 2019-06-13
CA3101298A1 (en) 2011-09-09
CN106188301A (zh) 2016-12-07
NZ602115A (en) 2014-12-24
PL3345615T3 (pl) 2020-07-13
CO6620068A2 (es) 2013-02-15
SI2542257T1 (en) 2018-01-31
CA2791685C (en) 2019-07-23
US20120108796A1 (en) 2012-05-03
PH12018500641A1 (en) 2019-07-29
ES2642512T3 (es) 2017-11-16
JP6025570B2 (ja) 2016-11-16
HK1232232A1 (zh) 2018-01-05
CA2976671C (en) 2021-01-12
EA201290849A1 (ru) 2013-05-30
JP2013520996A (ja) 2013-06-10
AU2011223710A1 (en) 2012-09-20
KR20130004586A (ko) 2013-01-11
PL2542257T3 (pl) 2018-01-31
CU20120126A7 (es) 2013-01-30
CN110835373A (zh) 2020-02-25
EA032189B1 (ru) 2019-04-30
US8481030B2 (en) 2013-07-09
KR20190047135A (ko) 2019-05-07
CU23982B1 (es) 2014-03-26
CN105001335A (zh) 2015-10-28
HRP20171472T1 (hr) 2017-12-01
EP2542257A1 (en) 2013-01-09
EP2542257B1 (en) 2017-07-05
HRP20192295T1 (hr) 2020-03-20
KR101807894B1 (ko) 2017-12-12
EP2542257A4 (en) 2013-11-13
ECSP19025350A (es) 2019-04-30
NZ702494A (en) 2016-09-30
PH12018500639A1 (en) 2019-07-29
ES2765418T3 (es) 2020-06-09
SG10201502587SA (en) 2015-06-29
CN102939098B (zh) 2016-08-03
SI3345615T1 (sl) 2020-03-31
IL262444A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TN2012000144A1 (en) Dll4-binding molecules
EP2582722A4 (en) ANTIBODIES AGAINST GD2
AU2011328009A8 (en) Compounds and methods for treating pain
JO2576B1 (en) Antibodies
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
IN2014DN10386A (es)
GB201109238D0 (en) Antibodies
IN2014DN08385A (es)
UY33219A (es) Cetoenoles cíclicos para terapias
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth